OCX - oncocyte.com Quick Liquidity Indicator

The biopharmaceutical business of OncoCyte Corporation (OCX) relies on a steady demand for medications, although sanctions could disrupt component supplies. Diagnostic accuracy depends on the prompt transportation of samples in thermal boxes. The price evolution of OncoCyte Corporation (OCX) on the GURU.Markets platform is currently at 3.84. Meanwhile, the development of transplantation tests requires scaling up to achieve full self-sufficiency.

OncoCyte Corp. (OCX) - Quick Ratio from 07/04/2022 to 06/18/2025

OCX (oncocyte.com): analytical breakdowns and indicator data

- market value and analyst target forecast:

Price Chart OncoCyte Corp.|OCX - Fair Value Consensus

- market capitalization statistics:

Market Valuation OncoCyte Corp.|OCX - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share OncoCyte|OCX - Book Capitalization|Market Value to Book Value Ratio oncocyte.com|OCX - Total Business Assets

- business debt structure and liquidity details:

- earnings and valuation multiples indicators:

OCX - Net Financial Result

Fundamental valuation:OncoCyte Corp., OCX

Short-term solvency assessment is critical for capital-intensive companies. This quick ratio measures the ability of OncoCyte Corporation (OCX) to settle obligations using its most liquid assets, completely excluding slow-moving inventories. The quick ratio trend reveals a risk of excessive capital freezing. For a biopharmaceutical business operating within strict FDA frameworks, such a check confirms financial stability while adhering to rigorous medical regulations.

Analysis of competing companies